Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Cash from Financing Activities (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Cash from Financing Activities for 16 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 157.8% to $6.2 million in Q4 2025 year-over-year; TTM through Oct 2025 was $2.1 million, a 105.41% increase, with the full-year FY2025 number at -$25.0 million, down 133.74% from a year prior.
  • Cash from Financing Activities was $6.2 million for Q4 2025 at PharmaCyte Biotech, up from -$171543.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $87.4 million in Q4 2021 to a low of -$10.7 million in Q4 2024.
  • A 5-year average of $2.6 million and a median of -$2.1 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 3015.5% in 2021, then crashed 8376.76% in 2023.
  • PharmaCyte Biotech's Cash from Financing Activities stood at $87.4 million in 2021, then crashed by 103.87% to -$3.4 million in 2022, then soared by 122.12% to $748687.0 in 2023, then plummeted by 1534.56% to -$10.7 million in 2024, then skyrocketed by 157.8% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Cash from Financing Activities are $6.2 million (Q4 2025), -$171543.0 (Q2 2025), and -$3.9 million (Q1 2025).